Myeloid-derived suppressor cells contribute to bone erosion in collagen-induced arthritis by differentiating to osteoclasts

Journal of Autoimmunity

Volumn 65, Issue , 2015, Pages 82-89

  Zhang, Hui ^a   Huang, Yuefang ^a   Wang, Shuang ^a   Fu, Rong ^a   Guo, Chaohuan ^a   Wang, Hongyue ^a   Zhao, Jijun ^a   Gaskin, Felicia ^b   Chen, Jingxian ^a   Yang, Niansheng ^a   Fu, Shu Man ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Bone destruction; Collagen induced arthritis and rheumatoid arthritis; MDSC; Osteoclast; Osteoclast precursor

Indexed keywords

COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; IL1RN PROTEIN, MOUSE; NITRILE; SULFONE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE EROSION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; SUPPRESSOR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; COMPLICATION; DBA MOUSE; DRUG EFFECTS; EXPERIMENTAL ARTHRITIS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; TIBIA;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MICE; MICE, INBRED DBA; MYELOID CELLS; NF-KAPPA B; NITRILES; OSTEOCLASTS; RANK LIGAND; SULFONES; TIBIA;

EID: 84940094100     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.08.010     Document Type: Article

References (40)

1. Gravallese E.M. Bone destruction in arthritis. Ann. Rheum. Dis. 2002, 61(Suppl. 2):ii84-ii86.
2. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
3. McQueen F.M., Stewart N., Crabbe J., Robinson E., Yeoman S., Tan P.L., et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann. Rheum. Dis. 1998, 57:350-356.
4. Gravallese E.M., Harada Y., Wang J.T., Gorn A.H., Thornhill T.S., Goldring S.R. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 1998, 152:943-951.
5. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
6. Quinn J.M., Elliott J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998, 139:4424-4427.
7. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science 2000, 289:1508-1514.
8. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res. Ther. 2007, 9:203.
9. Adamopoulos I.E., Mellins E.D. Alternative pathways of osteoclastogenesis in inflammatory arthritis. Nat. Rev. Rheumatol. 2015, 11:189-194.
10. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
11. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 2010, 22:238-244.
12. Haile L.A., von Wasielewski R., Gamrekelashvili J., Kruger C., Bachmann O., Westendorf A.M., et al. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 2008, 135:871-881. 81 e1-5.
13. + cells suppress B cell differentiation and lupus-like disease in lupus-prone male mice. Arthritis Rheum. 2013, 65:2392-2402.
14. + myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis. J. Immunol. 2012, 189:4295-4304.
15. Zhang H., Wang S., Huang Y., Wang H., Zhao J., Gaskin F., et al. Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation. Clin. Immunol. 2015, 157:175-186.
16. Guo C., Hu F., Yi H., Feng Z., Li C., Shi L., et al. Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. Ann. Rheum. Dis. 2014, 10.1136/annrheumdis-2014-205508.
17. Wang H., Zhao J., Zhang H., Huang Y., Wang S., Tu Q., et al. CARD11 blockade suppresses murine collagen-induced arthritis via inhibiting CARD11/Bcl10 assembly and T helper type 17 response. Clin. Exp. Immunol. 2014, 176:238-245.
18. Stoll S., Delon J., Brotz T.M., Germain R.N. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 2002, 296:1873-1876.
19. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 2002, 3:889-901.
20. Scholtysek C., Krönke G., Schett G. Bone resorption assay. Bio-protocol 2014, 4(14):e1187.
21. Kanehisa J., Yamanaka T., Doi S., Turksen K., Heersche J.N., Aubin J.E., et al. A band of F-actin containing podosomes is involved in bone resorption by osteoclasts. Bone 1990, 11:287-293.
22. Swaroop N., Chen F., Wang L., Dokka S., Toledo D., Rojanasakul Y. Inhibition of nuclear transcription factor-kappaB by specific IkappaB kinase peptide inhibitor. Pharm. Res. 2001, 18:1631-1633.
23. Dai S., Hirayama T., Abbas S., Abu-Amer Y. The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J. Biol. Chem. 2004, 279:37219-37222.
24. Eastgate J.A., Symons J.A., Wood N.C., Grinlinton F.M., di Giovine F.S., Duff G.W. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988, 2:706-709.
25. Abramson S.B., Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatol. Oxf. 2002, 41:972-980.
26. De Klerck B., Carpentier I., Lories R.J., Habraken Y., Piette J., Carmeliet G., et al. Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b+ myelopoiesis. Arthritis Res. Ther. 2004, 6:R220-R231.
27. Walsh M.C., Kim N., Kadono Y., Rho J., Lee S.Y., Lorenzo J., et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 2006, 24:33-63.
28. Ritchlin C.T., Haas-Smith S.A., Li P., Hicks D.G., Schwarz E.M. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Investig. 2003, 111:821-831.
29. Chiu Y.G., Shao T., Feng C., Mensah K.A., Thullen M., Schwarz E.M., et al. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res. Ther. 2010, 12:R14.
30. Denk A., Wirth T., Baumann B. NF-kappaB transcription factors: critical regulators of hematopoiesis and neuronal survival. Cytokine Growth Factor Rev. 2000, 11:303-320.
31. Weih F., Carrasco D., Durham S.K., Barton D.S., Rizzo C.A., Ryseck R.P., et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 1995, 80:331-340.
32. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 1997, 11:3482-3496.
33. Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., et al. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J. Cell Biol. 2000, 148:333-342.
34. Kwan Tat S., Padrines M., Theoleyre S., Heymann D., Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004, 15:49-60.
35. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 2000, 191:275-286.
36. Ishimi Y., Miyaura C., Jin C.H., Akatsu T., Abe E., Nakamura Y., et al. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol. 1990, 145:3297-3303.
37. Yago T., Nanke Y., Kawamoto M., Furuya T., Kobashigawa T., Kamatani N., et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res. Ther. 2007, 9:R96.
38. Kim J.H., Jin H.M., Kim K., Song I., Youn B.U., Matsuo K., et al. The mechanism of osteoclast differentiation induced by IL-1. J. Immunol. 2009, 183:1862-1870.
39. O'Gradaigh D., Ireland D., Bord S., Compston J.E. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann. Rheum. Dis. 2004, 63:354-359.
40. Jiang Y., Genant H.K., Watt I., Cobby M., Bresnihan B., Aitchison R., et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 2000, 43:1001-1009.